Published in Cancer Weekly, May 31st, 1999
"The widely-held view by third-party payers is that clinical trials are much more expensive than standard treatment," said Steve Alberts, MD, Mayo Clinic oncologist and the study's principal investigator. "We now know that costs are not budget-breaking. We hope this will encourage reimbursement by third-party payers, which will translate into better access to clinical trials for patients. This access in turn...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.